INVENTIVA (EPA:IVA) | WebDisclosure

Basculer en Français

10943	Companies
239136	Keywords
167970	Articles
128565	Press releases

Home
Companies
INVENTIVA

PRESS RELEASE

published on 04/24/2025 at 22:01, 1 year 4 months ago

Inventiva annonce la publication dans Clinical Gastroenterology and Hepatology de l’analyse de nouvelles signatures de biomarqueurs prédictives de la réponse histologique chez les patients atteints de MASH traités par lanifibranor
Inventiva annonce la publication des résultats de l'analyse de nouvelles signatures de biomarqueurs non invasifs prédictives de la réponse histologique chez les patients atteints de MASH traités par lanifibranor

Biomarqueurs Inventiva MASH Lanifibranor Réponse Histologique
BRIEF

published on 04/15/2025 at 22:05, 1 year 4 months ago

Inventiva Files 2024 Financial Documents with Regulatory Agencies

Biopharmaceutical Regulatory Filing Inventiva MASH 2024 Financials
BRIEF

published on 04/15/2025 at 22:05, 1 year 4 months ago

Inventiva dépose ses documents financiers 2024 auprès des agences réglementaires

Biopharmaceutique Dépôt Réglementaire Résultats Financiers 2024 Inventiva ÉCRASER
PRESS RELEASE

published on 04/15/2025 at 22:00, 1 year 4 months ago

Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F
Inventiva files its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F with the AMF and SEC. Documents accessible on Inventiva's website and regulatory authorities' sites

2024 Form 20-F Registration Document Clinical-Stage Biopharmaceutical Inventiva
PRESS RELEASE

published on 04/15/2025 at 22:00, 1 year 4 months ago

Inventiva annonce le dépôt de son Document d’Enregistrement Universel 2024 et de son Rapport Annuel 2024 (« Form 20-F »)
Inventiva dépose son Document d’Enregistrement Universel 2024 et son Rapport Annuel 2024 (Form 20-F) auprès de l’AMF et de la SEC. Les documents sont disponibles sur les sites internet respectifs

AMF SEC Inventiva Rapport Annuel 2024 Document D'Enregistrement Universel 2024
BRIEF

published on 03/26/2025 at 21:05, 1 year 5 months ago

Inventiva dévoile ses résultats financiers 2024 et ses projets stratégiques

Réorganisation Stratégique Résultats Financiers 2024 Recherche & Développement Lanifibranor Financement Structuré
BRIEF

published on 03/26/2025 at 21:05, 1 year 5 months ago

Inventiva unveils its 2024 financial results and strategic projects

Strategic Reorganization 2024 Financial Results Research & Development Lanifibranor Structured Financing
PRESS RELEASE

published on 03/26/2025 at 21:00, 1 year 5 months ago

Inventiva publie ses résultats financiers annuels 2024 et fait le point sur son activité
Inventiva publie ses résultats financiers annuels 2024 et fait le point sur son activité avec chiffre d'affaires de 9,2 millions d'euros, trésorerie à 96,6 millions d'euros et levée de 116 millions d'euros

Chiffre D'affaires Résultats Financiers Financement Trésorerie Inventiva
PRESS RELEASE

published on 03/26/2025 at 21:00, 1 year 5 months ago

Inventiva reports its 2024 full year results and provides a business update
Inventiva reports its 2024 full year financial results with revenues of €9.2 million, cash equivalents of €96.6 million and a structured financing of up to €348 million. Significant progress in the NATiV3 Phase 3 trial of lanifibranor for MASH. Pipeline prioritization plan presented

Revenues Financial Results Inventiva Cash Equivalents NATiV3 Phase 3 Trial
BRIEF

published on 03/19/2025 at 21:05, 1 year 5 months ago

Inventiva Announces 2024 Full-Year Financial Results Schedule

Financial Results Webcast Inventiva Lanifibranor MASH Treatment

Accesswire

Published on 09/08/2026 at 09:05, 55 minutes ago

Battery X Metals to Appoint Accomplished Technology and Consumer Brands Executive Nicholas Reichenbach to Board of Directors
Published on 09/08/2026 at 09:05, 55 minutes ago

BioNxt Advances Sublingual Everolimus ODF for Organ Transplant Rejection with Initiation of Large-Animal Pharmacokinetic Study
Published on 09/08/2026 at 09:01, 59 minutes ago

Apex Expands Trinity Zone with Step-out Hole Returning 197.5 m Interval of 2.12% REO at the Rift Rare Earth Project in SE Nebraska
Published on 09/08/2026 at 01:45, 8 hours 15 minutes ago

Tunkillia Environmental Scoping Report Approved
Published on 09/05/2026 at 04:05, 3 days 5 hours ago

Pelican AI Corp. Announces Proposed Share Issuances and Litigation Update

View all ACCESSWIRE

EQS Group

Published on 09/08/2026 at 09:46, 13 minutes ago

EQS-Adhoc: PSI Software SE and Zest Bidco GmbH enter into delisting agreement; public delisting acquisition offer announced
Published on 09/08/2026 at 09:35, 24 minutes ago

EQS-WpÜG: Takeover Offer / Target company: PSI Software SE; Bidder: Zest Bidco GmbH
Published on 09/08/2026 at 09:30, 29 minutes ago

TCL Earns Over 30 Global Honors at IFA 2026, Recognizing Cutting-Edge Innovations Across Display, AI and Smart Living
Published on 09/08/2026 at 09:05, 54 minutes ago

Mix Markt Süd Strengthens Fresh Food Retail Operations with SOLUM's Electronic Shelf Labels and Digital Signage
Published on 09/08/2026 at 09:05, 54 minutes ago

Insightec Marks 10,000 Patients Treated Across Europe, Middle East and Africa (EMEA) With MR-Guided Focused Ultrasound

Les Echos

Published on 09/08/2026 at 08:30, 1 hour 30 minutes ago

Klarsen : calendrier de communication
Published on 09/07/2026 at 19:55, 14 hours 4 minutes ago

TFF GROUP CREE TFF UPCYCLING
Published on 09/07/2026 at 19:00, 15 hours ago

Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 4 septembre 2026
Published on 09/07/2026 at 19:00, 15 hours ago

Information concerning the total number of voting rights and shares in the share capital as of September 4, 2026
Published on 09/07/2026 at 18:05, 15 hours 55 minutes ago

AXA: Information relating to the number of voting rights and shares making up the share capital on 31/08/2026

View all LES ECHOS COMFI WIRE